Medication Use Up for OUD as Diagnoses Decline Among Medicaid Beneficiaries

Why It Matters

The trend signals that policy‑driven expansion of MOUD is reaching more Medicaid patients, potentially curbing opioid‑related mortality, yet persistent state gaps threaten nationwide impact.

Key Takeaways

• OUD diagnoses fell from 4.2% to 3.6% (2019‑2023)
• MOUD receipt rose from 60.0% to 69.1% among diagnosed
• Vermont, RI, Maine >85% MOUD; GA, TX <46%
• OUD‑related hospital/ED visits dropped 0.3 percentage points
• State policies like SUPPORT Act and tele‑health drove MOUD growth

Pulse Analysis

The opioid crisis remains the leading cause of preventable death in the United States, and Medicaid beneficiaries bear a disproportionate share of overdose fatalities. Recent federal guidelines and the SUPPORT Act have broadened coverage for medication‑assisted treatment, while tele‑health reforms have lowered barriers for clinicians to prescribe buprenorphine and other MOUDs. These policy shifts set the stage for the study’s finding that, despite a modest decline in OUD diagnoses, more than two‑thirds of Medicaid patients with an OUD label now receive evidence‑based medication, a notable improvement from a decade ago.

Data from the Transformed Medicaid Statistical Information System reveal nuanced state‑level outcomes. New England states such as Vermont, Rhode Island, and Maine report MOUD receipt rates above 85%, reflecting aggressive Medicaid expansion and supportive prescribing regulations. Conversely, Southern states like Georgia, Texas, and Mississippi lag below 46%, underscoring the impact of lingering restrictions and limited provider capacity. The overall reduction in OUD‑related hospitalizations and emergency‑department visits, though modest, suggests that sustained medication use is translating into fewer acute crises.

For policymakers and health system leaders, the study underscores two imperatives: first, to replicate high‑performing state models that combine Medicaid reimbursement incentives, relaxed take‑home methadone rules, and robust tele‑health infrastructure; second, to target persistent geographic disparities through federal grants and state‑level legislative reforms. Continued monitoring of the OUD care cascade will be essential to gauge the long‑term effects of these interventions on overdose mortality and health‑care costs, guiding future investments in the nation’s most vulnerable populations.